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Thrombotic Thrombocytopenic Purpura or Disseminated Intravascular Coagulation? Diagnostic Dilemma in the ICU
Lindsay Gittens MSIV, Katherine Metcalf M.D., Nicholas C. Watson M.D.
Department of Anesthesiology, University of Massachusetts Medical School, Worcester, MA
Background Discussion
DIC and TTP are two causes of thrombocytopenia that require 
timely diagnosis and different treatments. Both conditions can be 
difficult to recognize as clinical presentations vary and current 
diagnostic criteria lack specificity1,2,3,4. DIC is a complex thrombo-
hemorrhagic condition that is always secondary to an underlying 
disorder, the most common causes being sepsis or trauma. It is 
primarily a clinical diagnosis that must be confirmed by laboratory 
data (see figure 2). There is, however, no single laboratory test that 
can establish or exclude the diagnosis2 TTP is a rare condition
The clinical differentiation between DIC and TTP can be a 
diagnostic challenge.  In our patient, the inconclusive DIC panel in 
addition to renal failure made TTP the most concerning alternative 
diagnosis. As mentioned previously, the literature shows that there is 
no conclusive diagnostic test for either condition, and diagnosis is 
based on clinical suspicion in conjunction with laboratory results. 
Our patient had symptoms and laboratory values that were 
consistent with both TTP and DIC, and both diagnosis were 
Figure 1.  Hospital Course of Thrombocytopenia                            Figure 3.  Weighing the Data
Baseline HD1 HD2 HD3 HD4 HD5 HD6 HD7 HD8 HD9
platelets 310 111 53 48 24 25 21 41 76 153
Hb 13.5 14.5 12.2 13.1 10.4 8.5 7.2 8.4 8.4 7.1
BUN 13 13 19 35 48 71 103 124 99 86
creatinine .73 1.12 1.82 3.94 5.16 6.35 7.27 8.16 6.92 5.72
LDH 1964 2576 2642 1704 1191
FINDING SUPPORTS 
TTP
SUPPORTS 
DIC
Thrombocytopenia + +
Fibrin Degradation +
Figure 3.  Summary of the lab values for the patient
presented here.  Note that because of the numerous 
supporting features for TTP and DIC, it was not until
HD7 when the patient had spontaneous recovery of platelet
count that TTP was ruled out and DIC was determined to be
the final diagnosis.
     .      
characterized by systemic microvascular thrombosis, with an 
incidence of 4 to 11 cases per million people. Like DIC, TTP has no 
specific diagnostic test and it shares many of the clinical and 
laboratory features of DIC that can make the two diagnoses difficult 
to differentiate. Prompt recognition of TTP is warranted as it 
responds well to plasmapheresis, and without treatment it is 
associated with a high mortality rate1. Although clinical presentation 
and laboratory data often lead to the correct diagnosis, equivocal 
results can often preclude finding a clear etiology.
considered for the majority of her hospital course (figure 3).  It was 
ultimately the spontaneous recovery of her platelet count that ruled 
out TTP as the etiology.  The initial DIC panel on HD 4 was 
considered “inconclusive” because of the elevated fibrinogen and 
marginally elevated clotting times, but the literature shows that in the 
acute phase response there is shortening of activated partial 
thromboplastin time and increased fibrinogen concentrations2,3. 
Therefore a normal value for these measurements can not rule out 
DIC. As previously mentioned, the patient’s acute renal failure was 
another reason TTP was strongly considered. Literature shows, 
however that acute renal failure occurs infrequently in TTP Our
PT 13.1 12.6 13.9 15.7
PTT 36.1 26.4 34.6 33.3
fibrinogen 173 549 404 455 521 446
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ATIII? +
Fibrinogen normal +
LDH? +
PT?, PTT? +
Worsening Anemia +
Microangiopathic 
Hemolytic Anemia on 
blood smear
+
Figure 1. 
Abnormal values in red.
Normal values for our lab:
Platelets 140-440 x103/mm3
Hb 10-16 g/dL
BUN 7-23 mg/dL
C  0 6 1 3 /dL
Figure 2.  TTP vs DIC
Hospital Course
This is the case of a 77 year old female with PMH of spinal 
degeneration s/p multiple spinal surgeries, hypertension, and 
hyperlipidemia, who presented to the surgical ICU s/p T9-ileum 
posterior fusion transverse osteotomy, L1-L2 transforaminal lumbar 
interbody fusion, and T11-T12 posterior laminectomy. Her operative 
course was prolonged due to an incidental durotomy.  She required a 
phenylephrine infusion for the majority of the 11-hour case and fluid 
resuscitation of 3 units of PRBCs, 7700 ml of crystalloid, and 780 ml of 
cell saver. Blood Loss was estimated at 1500 ml and urine output was 
,        .  
patient’s renal failure was likely coincidental, secondary to an 
intraoperative insult.  Critical care patients often have anemia and 
thrombocytopenia and the etiology is unlikely to be TTP even if 
MAHA is present1.
Our case demonstrates the difficulties in confirming a 
diagnosis with sensitive but nonspecific criteria. TTP and DIC share 
similar characteristics, but missing a timely diagnosis of TTP can 
prove fatal for the patient without treatment. 
 
ADAMST13 gene 
negative
+
Renal failure (ATN) +
Encephalopathy +/-
Spontaneous recovery 
of platelet count
+
Diagnostic Criteria Differential Pathophysiology Laboratory Values Treatment 
r . - . mg
LDH 110-240 IU/L
PT 9.6-12.4 seconds
PTT 22-34 seconds
Fibrinogen 150-400 mg/dL
1150 ml. Postoperatively she went to the SICU hemodynamically 
stable and intubated. By HD2, her renal function had worsened and 
she had developed thrombocytopenia (figure 1).  A FENa done at the 
time was consistent with intrinsic renal damage.  Despite being fully 
resuscitated and extubated on HD2, her renal functioned continued to 
worsen and her platelets continued to drop. HIT and sepsis were ruled 
out, but a peripheral blood smear obtained on HD3 showed 
microangiopathic hemolytic anemia, turning the differential diagnosis 
to TTP or DIC.  By then, the patient was also noted to have oozing 
from an antecubital IV site.  A DIC panel done on HD4 was 
inconclusive, having revealed an elevated FDP and D-dimer with a low 
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TTP
(1) Unexplained microangiopathic
hemolytic anemia and (2) 
thrombocytopenia (with or without 
neurologic involvement, renal 
failure, and fever)5.
ITP, 
autoimmune 
hemolytic 
anemia, 
HUS, DIC, 
PNH.
Severe deficiency of von 
Willebrand factor cleaving 
protease as a result of 
mutation in the ADAMTS13 
gene leading to systemic 
microvascular thrombosis5.
(1) ?hct, (2) ?Platelets (in 
absence of leukopenia), and (3) 
evidence of microangiopathic
hemolytic anemia: schistocytes
and reticulocytes on peripheral 
smear, ? LDH and indirect-
reacting bilirubin, and negative 
direct Coomb’s test1.
Plasma 
exchange and 
glucocorticoids1.
(1) An underlying disease known to 
b i d i h DIC ( S i
Liver failure, 
HIT TTP
The systemic formation of 
fib i l i f i d
(1) ?PT, (2)?PTT,
(3)? l l (4)
Aggressive 
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ATIII but an elevated fibrinogen and marginally elevated PT and PTT. 
TTP was still being considered in the setting of renal failure which was 
likely acute tubular necrosis. On HD6 the patient developed uremic 
encephalopathy and she required dialysis. After the patient’s platelets 
dropped to 21, plasma exchange was scheduled for HD7, but before 
initiating this treatment her platelets began to improve. The fact that 
her thrombocytopenia improved without intervention ruled out TTP as 
the etiology.  She was transfered to the floor on HD9 with a diagnosis 
of DIC and AKI, likely due to an intra-operative event. 
6. Fakhouri F. and Fremeaux-Bacchi V. Does hemolytic uremic syndrome differ from 
thrombotic thrombocytopenic purpura? Nature Clinical Practice Nephrology. 
2007;3(12):679-87.
Abbreviations
-DIC= Disseminated Intravascular 
Coagulation
-HD= Hospital day
-TTP= Thrombotic 
Thrombocytopenic Purpura
-MAHA= 
Microangiopathic 
Hemolytic Anemia
DIC
e assoc ate  w t   eg. eps s, 
trauma, cancer, vascular disorders, 
toxins, or immunologic disorders.
(2) thrombocytopenia, (3) 
prolongation of clotting times, (4) 
presence of fibrin-degradation 
products, and (5) low levels of 
coagulation inhibitors2.
, , 
Vitamin K 
deficiency.
r n resu t ng rom ncrease  
generation of thrombin, the
simultaneous suppression of 
physiologic anticoagulation 
mechanisms, and the 
delayed removal of fibrin as a 
consequence of impaired 
fibrinolysis2.
p ate et count, 
?fibrinogen, (5)?D-dimer, (6)
?Fibrinogen degradation 
products, (7) ?fibrin monomer, 
and (8) peripheral blood smear 
showing shistocytes2.
treatment of 
underlying 
disease2.
